Avivagen Inc. (TSXV:VIV) (“Avivagen”) is pleased to announce that it has received approval for the use of OxC-beta™ Livestock in Broilers and Swine in Malaysia. With the addition of Malaysia, OxC-betaTM Livestock is now approved for use in eight markets worldwide, including the United States, Mexico, New Zealand, Taiwan, Thailand, Australia and the Philippines.

“We are very excited to secure approval for the use of OxC-betaTM Livestock in the fast-growing Malaysian market, where the planned move to antibiotic-free chicken production in 2020 presents us with an immediate opportunity for growth,” says Kym Anthony, Chief Executive Officer, Avivagen. “2019 has seen Avivagen secure key regulatory approvals in new markets and sign new distribution deals for OxC-BetaTM Livestock, laying important groundwork that we are confident sets the stage for positive momentum and sales growth in 2020 and beyond.”

With an estimated total annual feed production of 4.8 million metric tonnes in 2019, the Malaysian market is dominated by feed for poultry broilers and layersi. This demand has been driven by the growing popularity of chicken-based fast food restaurants in the region, including Kentucky Fried Chicken (KFC), Nando’s, The Chicken Rice Shop, Kenny Rogers Roasters, and Ayamas.ii Avivagen’s distribution partner in Malaysia, TLC Veterinary Services, is the principal supplier to farms that supply KFC, the leading fast food chain in Malaysia with over 600 restaurants.iii

The Malaysian government has stated a goal of targeting 2020 to produce antibiotic-free chickeniv. The approval of OxC-beta™ for Livestock ideally positions Avivagen to capitalize on an expected increased market for safe and effective antibiotic alternatives that will be needed to meet production demands under this country-wide mandate.

About Avivagen Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

About OxC-beta™ Technology and OxC-beta™ Livestock Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colours, and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic as an alternative to the antibiotics commonly added to livestock feeds. OxC-beta™ Livestock is currently available for sale in the Philippines, Taiwan, Thailand, New Zealand, Mexico, Australia and the U.S.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

Forward Looking Statements This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements set out in this news release relating to the distribution agreement in Malaysia, timing of the Malaysian government’s policy initiatives, Avivagen’s positioning and ability to take advantage of those initiatives, the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as well as fill a critical need for health support in certain livestock applications where antibiotics are precluded, Avivagen’s intention to accelerate market access and the commercial uptake of its OxC-beta™ Livestock product and the size of market opportunities are all forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, Avivagen’s distribution partner in Malaysia is under no obligation to purchase the product from Avivagen , the Malaysian government may change or eliminate its mandated timing for antibiotic free chicken, Avivagen’s products may not gain acceptance in Malaysia or allow Avivagen to take advantage of the Malaysian government’s policy initiatives, Avivagen’s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics in livestock feeds, new market access may not occur in the timeline or manner expected by Avivagen and the market opportunities may not be as large as Avivagen anticipates due to many factors, many of which are outside of Avivagen’s control. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Information as to market size if various jurisdictions is sourced by Avivagen from third parties. While Avivagen believes such third-party sources to be reliable, it has not independently verified such information and readers should not place undue weight on such information.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright © 2019 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.

i 2019 Alltech Global Feed Survey

ii US-Gain report: Malaysia Grain and Animal Feed-2018 GAIN Report # MY8002

iii https://kfc.com.my

iv : https://www.malaysiakini.com/news/333981

Avivagen Inc. Drew Basek Director of Investor Relations 100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733 E-mail: d.basek@avivagen.com

Kym Anthony CEO 100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164 Website: www.avivagen.com

Avivagen (TSXV:VIV)
Historical Stock Chart
Von Dez 2024 bis Jan 2025 Click Here for more Avivagen Charts.
Avivagen (TSXV:VIV)
Historical Stock Chart
Von Jan 2024 bis Jan 2025 Click Here for more Avivagen Charts.